TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding
Brief Summary: The many benefits of breastfeeding are well documented. However, because of the risk of mother-to-child transmission (MTCT) of HIV from an HIV infected mother to her infant, there is considerable concern over the practice, especially in developing countries. The purpose of this study is to determine the safety and effectiveness of the anti-HIV drug nevirapine (NVP) in preventing MTCT of HIV in breastfeeding infants born to HIV infected women in South Africa, Tanzania, Uganda, and Zimbabwe.


Options:
A: Arm Label: Control arm: HBIG & vaccine for infants; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TDF treatment arm; Type: EXPERIMENTAL; Interventions: Drug: TDF treatment | Intervention Type: DRUG; Name: TDF treatment; Assigned to Arm(s): TDF treatment arm
B: Arm Label: Blinded Phase: B/F/TAF; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF, Drug: ABC/DTG/3TC Placebo | Arm Label: Blinded Phase: ABC/DTG/3TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABC/DTG/3TC, Drug: B/F/TAF Placebo | Arm Label: Open-Label Phase; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF | Intervention Type: DRUG; Name: ABC/DTG/3TC; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC | Intervention Type: DRUG; Name: B/F/TAF; Assigned to Arm(s): Blinded Phase: B/F/TAF, Open-Label Phase | Intervention Type: DRUG; Name: ABC/DTG/3TC Placebo; Assigned to Arm(s): Blinded Phase: B/F/TAF | Intervention Type: DRUG; Name: B/F/TAF Placebo; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC
C: Arm Label: 2A; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 2A | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2B
D: Arm Label: Tenofovir disoproxil fumarate; Type: EXPERIMENTAL; Interventions: Drug: tenofovir disoproxil fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tenofovir disoproxil fumarate; Assigned to Arm(s): Tenofovir disoproxil fumarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding
Brief Summary: The many benefits of breastfeeding are well documented. However, because of the risk of mother-to-child transmission (MTCT) of HIV from an HIV infected mother to her infant, there is considerable concern over the practice, especially in developing countries. The purpose of this study is to determine the safety and effectiveness of the anti-HIV drug nevirapine (NVP) in preventing MTCT of HIV in breastfeeding infants born to HIV infected women in South Africa, Tanzania, Uganda, and Zimbabwe.


Options:
A: Arm Label: 2A; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 2A | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2B
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP and AZT | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP+AZT | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: NVP | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: AZT; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: NVP and AZT; Assigned to Arm(s): A | Intervention Type: DRUG; Name: NVP; Assigned to Arm(s): B | Intervention Type: DRUG; Name: NVP+AZT; Assigned to Arm(s): C
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3
D: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women
Brief Summary: The majority of HIV infected people worldwide became infected with the virus through heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women from becoming infected with HIV during sexual intercourse with an HIV infected partner. This study will test the safety and effectiveness of these gels.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BufferGel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: PRO 2000/5 Gel | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: BufferGel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PRO 2000/5 Gel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): 3
B: Arm Label: Placebo Vaginal Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Vaginal Ring | Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring, 25 mg | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Vaginal Ring; Assigned to Arm(s): Placebo Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring, 25 mg; Assigned to Arm(s): Dapivirine Vaginal Ring
C: Arm Label: Tenofovir 1% vaginal gel; Type: EXPERIMENTAL; Interventions: Drug: Tenofovir gel | Arm Label: Universal placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Universal placebo gel | Intervention Type: DRUG; Name: Tenofovir gel; Assigned to Arm(s): Tenofovir 1% vaginal gel | Intervention Type: DRUG; Name: Universal placebo gel; Assigned to Arm(s): Universal placebo gel
D: Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring | Arm Label: Placebo Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring; Assigned to Arm(s): Dapivirine Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Ring; Assigned to Arm(s): Placebo Ring

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Brief Summary: This study will assess the efficacy and safety of different treatment regimens of rituximab (MabThera®/Rituxan®), corticosteroids, and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA).


Options:
A: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab, Drug: corticosteroids | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate, Drug: placebo | Arm Label: 8; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate, Drug: corticosteroids, Drug: placebo | Arm Label: 9; Type: PLACEBO_COMPARATOR; Interventions: Drug: methotrexate, Drug: corticosteroids, Drug: placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4, 5, 6, 7, 8, 9 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1, 2, 3, 4, 5, 6 | Intervention Type: DRUG; Name: corticosteroids; Assigned to Arm(s): 2, 3, 5, 6, 8, 9 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 7, 8, 9

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.

Patient safety and quality of life will also be monitored throughout the study.


Options:
A: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
B: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
C: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
D: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.

Patient safety and quality of life will also be monitored throughout the study.


Options:
A: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.

Patient safety and quality of life will also be monitored throughout the study.


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.

Patient safety and quality of life will also be monitored throughout the study.


Options:
A: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
C: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
D: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples
Brief Summary: This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.


Options:
A: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Monthly placebo | Arm Label: Treatment arm; Type: EXPERIMENTAL; Interventions: Drug: Monthly antibiotic | Intervention Type: DRUG; Name: Monthly antibiotic; Assigned to Arm(s): Treatment arm | Intervention Type: DRUG; Name: Monthly placebo; Assigned to Arm(s): Sugar pill
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atazanavir, Drug: Didanosine, Drug: Efavirenz, Drug: Emtricitabine/Tenofovir disoproxil fumarate, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine, Drug: Tenofovir disoproxil fumarate, Drug: Zidovudine/Lamivudine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Atazanavir, Drug: Didanosine, Drug: Efavirenz, Drug: Emtricitabine/Tenofovir disoproxil fumarate, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine, Drug: Tenofovir disoproxil fumarate, Drug: Zidovudine/Lamivudine | Intervention Type: DRUG; Name: Atazanavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Emtricitabine/Tenofovir disoproxil fumarate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Tenofovir disoproxil fumarate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine/Lamivudine; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: In-school Sexual Health Education; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth-friendly health services; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth condom promotion & distribution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Community activities related to adolescent sexual health; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Intervention with Microfinance for AIDS and Gender Equity; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Phase 2, Open-Label Study of Fabrazyme (Recombinant Human a-Galactosidase A) Replacement Therapy in Pediatric Patients With Fabry Disease
Brief Summary: People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. This enzyme helps to break down and remove certain types of fatty substances called "glycolipids". These glycolipids are normally present within the body in most cells. In people with Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid levels (also referred to as "globotriaosylceramide" or "GL-3") in these tissues is thought to cause the clinical symptoms that are common to Fabry disease. Symptoms commonly appear during childhood with pain in the hands and feet. This study explored the safety, efficacy and pharmacokinetics of Fabrazyme in pediatric patients aged between 7 and 15 years.


Options:
A: Arm Label: Fabrazyme 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Arm Label: Fabrazyme 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 0.5 mg/kg | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 1.0 mg/kg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Fabrazyme (agalsidase beta); Type: ACTIVE_COMPARATOR; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Agalsidase alfa (Cohort 1); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Arm Label: Agalsidase Alfa (Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Intervention Type: DRUG; Name: Agalsidase alfa; Assigned to Arm(s): Agalsidase Alfa (Cohort 2), Agalsidase alfa (Cohort 1)
D: Arm Label: Fabrazyme; Type: EXPERIMENTAL; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme

Answer: D